Skip to search formSkip to main contentSkip to account menu

LY3009104

Known as: LY 3009104 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

baricitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
Background LY3009104 (LY) is a novel, oral inhibitor of the JAK1/JAK2 signalling pathway known to be important in the… 
2012
2012
12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)